OMNIX MEDICAL: UN PAPILLON CONTRE ACINETOBACTER BAUMANNII

New mechanism of action (MoA) addressing global increase of antimicrobial resistance (AMR) burden and shortage of potent anti-infectives  JERUSALEM, Israel, April 12, 2022 — Omnix

Entirely novel therapeutic principle to combat alarming worldwide rise of antimicrobial resistance (AMR) JERUSALEM, Israel, March 16, 2022 — Omnix Medical, a biopharmaceutical company developing

To encourage EU Member States to actively contribute to exchanges on AMR in the co-legislative process, the BEAM Alliance relies on a network of National